Pre-increment!Huaren Pharmaceutical: It is estimated that the net profit in the first quarter of 2022 will be 24.8267 million yuan to 28 million yuan, a year-on-year increase of 0% to 12.78% _ Oriental Fortune Net

　　Huaren Pharmaceutical(SZ 300110, closing price: 4.36 yuan) released on the evening of April 8performanceAnnouncement, it is expected to be attributable to listed companies in the first quarter of 2022shareholderofnet profitRMB 24.8267 million to RMB 28 million, a year-on-year increase of 0% to 12.78%; the main reason for the change in performance is that during the reporting period, the company continued to strengthen the construction of core products, core teams, and core customers, further improved sales models and sales channels, and actively participated in national , provincial and prefecture-level centralized procurement, strengthen market access, implement refined investment promotion, and actively explore incremental customers while stabilizing the stock, and the sales volume and sales revenue of self-produced drugs have steadily increased. In August 2021, the company through its wholly-owned subsidiary Xi’an QujiangHuaren PharmaceuticalCo., Ltd. acquired 100% equity of Xi’an Hengjuxing Pharmaceutical Co., Ltd. and indirectly held 100% equity of Anhui Hengjuxing Pharmaceutical Co., Ltd., which will be included in the consolidated statement from August 2021. Compared with the same period of the previous year, it contributed part of the shares during the reporting period. profit.

From January to December 2021,Huaren PharmaceuticalofOperating incomeThe composition is: the pharmaceutical industry accounts for 80.53%,Pharmaceutical businessaccounting for 19.47%.

The chairman and president of Huaren Pharmaceutical are Yang Xiaodong, male, 54 years old, with a Ph.D.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 91

Original title: Pre-increment! Huaren Pharmaceutical: It is estimated that the net profit in the first quarter of 2022 will be 24.8267 million yuan to 28 million yuan, a year-on-year increase of 0% to 12.78%